Corporate Action Notice

BNY MELLON

May 30, 2019

Rights Offer

BiondVax Pharmaceuticals Ltd.
DR CUSIP: 09073Q105
DR ISIN: US09073Q1058
Ratio (DRs :Underlying Shares): 1:40
DR Ticker Symbol: BVXV

BiondVax Pharmaceuticals Ltd. ("BiondVax") announced a nontransferable rights offer and holders of American Depositary Shares ("ADSs") as of the ADS record date will receive ADS rights which will entitle the rights holder to subscribe for new ADSs.

The details of the offer are as follows:

ADS rights distribution ratio: 0.537823255 ADS rights for every one (1) BiondVax ADS held on the ADS record date. Each ADS right will allow the holder to subscribe for one new ADS. Each ADS is equal to forty (40) ordinary shares. Fractional ADS rights will not be issued, and ADS right entitlements will be reduced to the next smaller whole number of ADS rights.

ADS subscription payment: To validly subscribe for new ADSs, holders of ADSs will need to deposit with the ADS rights agent $5.69 for each new ADS subscribed for or sought.

- ADS record date: **June 9, 2019**
- ADS rights CUSIP: TBD
- The ADS exercise period is June 10, 2019 until June 28, 2019.
- ADS rights expiration date is 5:00 p.m. New York time on June 28, 2019.
- Expected ADS issuance date on or about July 5, 2019
- The ADS rights are not transferable.
- Oversubscription ADS rights: Not Applicable
- Guarantee period: Not applicable.
- The exercise of ADS rights is irrevocable and may not be cancelled or modified.
- Unexercised ADS rights will expire worthless.

For information regarding the ADS rights offering, please contact Co. legal counsel: Mark Hamilton, ADV. at markhamilton@pearlcohen.com or by phone at +972-(0)3-3039063.

To learn more about DRs, please contact DRBrokerSolutions@bnymellon.com or visit our website at adrbnymellon.com.

PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.

Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.